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L E T T E R  T O  T H E  E D I T O R
Definition, aims, and implementation of GA2LEN/HAEi 
Angioedema Centers of Reference and Excellence
To the Editor,
GA2LEN, the Global Allergy and Asthma European Network, and 
HAE international (HAEi), the global umbrella organization for the 
world's hereditary angioedema (HAE) patient groups, have launched 
their joint ACARE (Angioedema Center of Reference and Excellence) 
program, within GA2LEN’s center of reference and excellence 
(CORE) initiative. Angioedema is a common, heterogeneous, often 
debilitating and chronic condition and is frequently a challenge for 
physicians and affected patients, especially patients suffering from 
recurrent attacks. Additionally, it can be a challenge for some pa-
tients to understand the underlying etiology of their angioedema 
(Table 1). GA2LEN’s CORE networks, such as UCARE for urticaria 
and ADCARE for atopic dermatitis, help to improve the manage-
ment of difficult-to-treat conditions. Here, we describe the aims, re-
quirements, provisions, application process, audit, and accreditation 
protocol for GA2LEN/HAEi ACAREs. ACAREs aim to provide excel-
lence in angioedema management, increase the knowledge of an-
gioedema through research and education, and promote advocacy 
activities that raise angioedema awareness. To become a certified 
ACARE, angioedema centers must fulfill 32 requirements, defined 
by specific provisions that will be assessed during an audit visit. 
The ACARE program will result in a strong network of angioedema 
specialists, promote angioedema research and awareness, and har-
monize and improve angioedema management globally. ACAREs will 
expand access to modern angioedema medicines in countries where 
they are available and help to bring them to countries where they 
are not.1
This document summarizes the aims of GA2LEN/HAEi 
Angioedema Centers of Reference and Excellence (ACAREs) and 
elaborates the requirements that ACAREs must fulfill to become 
certified. It also provides (see Appendix S1) background informa-
tion on GA2LEN and HAEi, including HAEi member organizations 
and regional patient advocates, on why we need an Angioedema 
Center of Reference and Excellence (ACARE) program and network, 
and on the accreditation and certification process, governance and 
funding, and on the interaction with other GA2LEN networks of cen-
ters of reference and excellence. The protocols, aims, requirements, 
and provisions related to becoming a certified ACARE are based 
on (a) the experience of the GA2LEN UCARE network and (b) input 
from angioedema patients, general practitioners, and angioedema 
specialists.
What are the aims of GA2LEN/HAEi ACAREs? The aims of 
ACAREs are to set the global standard for excellence in comprehen-
sive angioedema care through research, education, advocacy, and 
interaction among ACAREs. By serving as referral centers for the di-
agnosis and management of patients with angioedema, ACAREs will 
complement the local healthcare system. ACAREs aim to increase 
knowledge and awareness of angioedema.
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TA B L E  1   Classification of angioedema
Bradykinin-mediated angioedema Mast cell mediator-mediated angioedema
Unknown 
mediator
C1-INH deficiency/
defect C1-INH normal IgE mediated Non-IgE mediated  
Inherited Acquired Inherited Acquired    
HAE-1
HAE-2
AAE-C1-
INH
HAE nC1-INH (HAE-
FXII, HAE-ANGPTI, 
HAE-PLG, HAE-
KNG1, HAE-UNK)
AE due to medication 
that interferes with 
BK degradation, eg 
ACEi
Angioedema with or 
without wheals in 
patients with urticaria
Anaphylaxis
Angioedema with or 
without wheals in 
patients with urticaria
Idiopathic AE
Abbreviations: AAE-C1-INH, acquired angioedema due to C1-inhibitor deficiency; ACEI-AE, angiotensin-converting enzyme inhibitor-induced 
angioedema; BK, bradykinin; HAE nC1-INH, hereditary angioedema with normal C1-inhibitor levels, either due to a mutation in factor XII (F12), 
angiopoietin-1 (ANGPT1), plasminogen (PLG), kininogen-1 (KNG1), or unknown (UNK) (HAE-FXII, HAE-ANGPTI, HAE-PLG, HAE-KNG1, HAE-UNK); 
HAE-1, hereditary angioedema due to C1-inhibitor deficiency; HAE-2, hereditary angioedema due to C1-inhibitor dysfunction.
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What are the requirements for GA2LEN/HAEi ACAREs? ACAREs 
are required to demonstrate excellence in the management of an-
gioedema, research activities, efforts in education, and advocacy ac-
tivity. ACAREs need to fulfill 32 requirements, which are explained 
in the audit checklist (Figure 1A). This checklist includes specific 
deliverables for each requirement. For example, the requirement to 
know and follow international guidelines and consensus documents 
for angioedema (Requirement #16) entails that physicians and other 
ACARE healthcare professionals have read and understood the cur-
rent versions of these guidelines and consensus documents and that 
their recommendations are implemented in their center.
These guidelines and consensus documents include, for exam-
ple, the international WAO/EAACI guideline for HAE, the EAACI/
GA2LEN/EDF/WAO guideline for urticaria, the International/
Canadian hereditary angioedema guideline,2-5 the international con-
sensus on the diagnosis and management of pediatric patients with 
hereditary angioedema with C1 inhibitor deficiency, the international 
consensus on the use of genetics in the management of HAE,6 and 
the international consensus and practical guidelines on the gyneco-
logic and obstetric management of female patients with hereditary 
angioedema caused by C1 inhibitor deficiency.7 The deliverables for 
this requirement are that (a) current guideline and consensus docu-
ment versions are present (paper or electronic version) at the cen-
ter, (b) ACARE staff can answer questions on the recommendations 
these documents provide, and (c) ACARE physicians can show, upon 
request, by use of a patient file, that patient management decisions 
are based on guideline recommendations (Figure 1B).
This publication marks our intent to start the implementation 
of the GA2LEN/HAEi ACARE initiative. Specialty centers for an-
gioedema have started to apply to become ACAREs, and audits and 
certifications are ongoing (Figure 1B). We expect that most GA2LEN 
UCARE centers and many angioedema specialty centers will be-
come ACAREs in the near future. We predict and hope that by 2022, 
GA2LEN/HAEi ACAREs will be established in every continent. This 
will result in a strong global network of angioedema specialists, pro-
mote angioedema research, and harmonize and improve angioedema 
management worldwide. GA2LEN and HAEi will measure the impact 
of ACAREs over time and document and report the benefits of this 
initiative. ACARE network activities and a current list of ACAREs are 
posted on the network's website (www.acare -netwo rk.com).
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